Business
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. (" Theralase®...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological AssociationTORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators (\"PIs\") at the Canadian Urological Association (\"CUA\") Bladder Cancer Forum and the American Urology Association (\"AUA\"), respectively.Study II is a Phase II clinical study that provides a Study Procedure (Study Drug activated by a Study Device) for patients diagnosed with Bacillus Calmette Guerin (\"BCG\")-Unresponsive Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\").An advisory board meeting is scheduled to take place on April 12, 2024, during the Bladder Cancer Forum 2024 located in Toronto, Ontario to provide an update to all Canadian Principal Investigators (\"PIs\") of the Study II interim clinical data and to discuss opportunities for patient enrollment.An advisory board meeting is scheduled to take place on May 4th, 2024, during the 2024 American Urology Association (\"AUA\") meeting in San Antonio, Texas to provide an update to all Canadian and US-based PIs of the Study II interim clinical data and to discuss opportunities for patient enrollment.Arkady Mandel MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, \"Patients with BCG-Unresponsive NMIBC CIS have limited treatment options other than bladder removal surgery. We look forward to discussing the strong, interim clinical data from Study II with the PIs of the study, who are key opinion leaders in the Canadian and US urologic community. The interim clinical data to be presented details the safety and efficacy of Ruvidar™-based photodynamic therapy PDT for the treatment of BCG-Unresponsive NMIBC CIS. The current interim Phase II clinical study analysis demonstrates a significant clinical advantage of the Theralase® technology in the current tre...